Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $9.46M rose 0.2% year over year, ahead of the -16.1% change in trailing-twelve-month gross profit. Sequentially, it fell 18.9% from the prior quarter. Over 3 fiscal years it compounded at -1.2% a year.

Context

  • Gross profit amounted to 87.3% of revenue in FY2025, down 3.9 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.2% holds above the trailing-twelve-month pace of -16.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.46M-18.9% QoQ
Last fiscal yearDec 2025
$45.25M-22.1% YoY
LTMMar 2026
$45.4M-16.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.2%——
1 year-22.1%——
3-year CAGR-1.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
45.25M USD
Year-over-year change
-22.1%
4-year CAGR
+3.7%

Gross Profit vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.1% is the 7th highest of 9, against a peer median of +8.4%.
  • Gross profit amounts to 87.2% of revenue for OCUL, versus a peer median of 77.8%.
OCUL Competitors
Gross Profit for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$3.04B USD+9.3%+7.5%57.2%
GKOSGlaukos CorporationLTM Jun 2026$484.88M USD+46.7%+22.5%79.1%
STAASTAAR Surgical CompanyLTM Apr 2026$221.94M USD+7.4%-6.5%76.4%
HROWHarrow Health, Inc.LTM Mar 2026$199.11M USD+25.5%+47.9%74.1%
OCULOcular Therapeutix, Inc.LTM Mar 2026$45.4M USD-16.1%-1.2%87.2%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$5.83M USD-88.9%-4.0%76.5%
OCGNOcugen, Inc.LTM Mar 2026$4.47M USD-1.3%-6.6%100.0%
KODKodiak Sciences Inc.LTM Sep 2026$0 USD+100.0%——
SGPSpyGlass Pharma, Inc. Common StockFY2025-$612K USD———
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M USD-4457.3%—360.9%
OCSOculis Holding AGLTM Mar 2026-CHF 14.56M CHF——2889.4%
Peer median (excluding OCUL) —+8.4%+1.8%77.8%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.